 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning University of Washington
|
-
VentriPoint, University of Washington Sign Research and Technology Development Agreement
(05/05/2008)
Projects Focus on Completion of the Congenital Heart Disease Database and the Further Transition of Knowledge and Processes to VentriPoint for the Development of the VentriPoint Diagnostic System
VentriPoint(TM) Diagnostics Ltd. announced that it has finalized a research and technology development agreement with the University of Washington to collaborate on projects that will enhance and broaden the VentriPoint Diagnostic System (VDS) ...
-
Osmetech licenses VKOR pharmacogenetic marker for warfarin dosage management from University of Washington
(03/13/2007)
Osmetech plc announced that it has taken a worldwide non-exclusive license from the University of Washington (UW) to Vitamin K Epoxide Reductase (VKOR) gene polymorphisms. This gene is a key diagnostic marker for the management of warfarin dosage. ...
-
Amgen Foundation Launches $25 Million Undergraduate Research Program
(10/23/2006)
As part of its mission to advance science education, the Amgen Foundation announced its partnership with 10 universities to provide hundreds of selected undergraduate students an opportunity to engage in a fully funded, hands-on research experience ...
-
Researchers Identify New Protein Biomarker Candidates That May Lead To Better Diagnosis And Treatment For Age-Related Diseases
(08/25/2006)
Alzheimer's Disease, Parkinson's Disease and Dementia with Lewy Bodies Targeted in Protein Study Enabled by Applied Biosystems/MDS SCIEX's Advanced Technologies
Applied Biosystems, an Applera Corporation business, and its joint venture partner, MDS Sciex, a division of MDS Inc., announced the outcome of the scientific research community's most extensive, spinal fluid-based protein study on neurodegenerative ...
-
Geron publishes studies demonstrating engraftment of human embryonic stem cell-derived cardiomyocytes in the rodent heart
(09/05/2005)
Geron Corporation announced the publication of studies showing that cardiomyocytes differentiated from human embryonic stem cells (hESCs) engraft when transplanted into the rat heart. The results provide proof of concept that transplanted ...
-
Pharmaceutical marketing tactics hold little sway with prescribing physicians
(12/09/2004)
Pharmaceutical drug companies spend upward of $25 billion per year on promoting new drugs and distributing free samples to doctors, but new research shows such marketing devices have little impact on physicians and their prescribing behavior. ...
|
|
|
|
|
Top
